FDA approves Biostar’s Phase II/III plans with utidelone injectable for NSCLC
Pharmaceutical Technology
JUNE 16, 2023
Designated as BG01-2202, this latest trial will be an open-label, randomised, controlled clinical study of UTD1 versus chemotherapy drug docetaxel. A Phase III study to evaluate UTD1 versus docetaxel in patients that have failed chemotherapy with a platinum-containing regimen is also currently underway in China. ORR, 81.0%
52 
Let's personalize your content